Given the multiple functions of PPARγ activation in lung cancer, PPARγ agonists included thiazolidinediones and non-thiazolidinediones have been used as therapeutic agents to tackle lung cancer in preclinical and clinical studies. Here, PPARG is linked to lung carcinoma.